Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gingipain HRgpA (Arginine-specific gingipain A) is a major extracellular cysteine protease produced by the gram-negative bacterium Porphyromonas gingivalis, a primary pathogen in chronic periodontitis [1]. Unlike its counterpart RgpB, HRgpA is a large complex consisting of a catalytic domain and several non-catalytic adhesion/hemagglutinin domains, which facilitate bacterial attachment to host tissues and the acquisition of essential nutrients like heme [2][4]. Biologically, HRgpA plays a critical role in host immune system evasion by degrading cytokines, complement proteins, and antimicrobial peptides, while also contributing to tissue destruction through the breakdown of extracellular matrix proteins [3]. Recent clinical research has identified gingipains, including HRgpA, in the brains of Alzheimer's disease patients, suggesting a role in neurodegeneration via the promotion of tau phosphorylation and neurotoxicity [2]. Therapeutic strategies focus on small-molecule inhibitors that target the enzyme's catalytic site to block its proteolytic activity, with compounds like COR271 being investigated for their potential to mitigate both periodontal damage and associated systemic or neurological pathologies [2]. Sources: [1] UniProt (P28784): RGP1_PORGI - Arginine-specific gingipain A. [2] Dominy SS, et al. (2019). "Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors." Science Advances. [3] Imamura T. (2003). "The role of gingipains in the pathogenesis of periodontal disease." Journal of Periodontology. [4] Potempa J, et al. (2015). "Gingipains: the major virulence determinants of Porphyromonas gingivalis." Molecular Oral Microbiology.
Inhibition of the cysteine protease catalytic activity by binding to the active site, thereby preventing the cleavage of host proteins and bacterial nutrient acquisition.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arginine-specific gingipain A (HRgpA).